KLRS
Kalaris Therapeutics, Inc.Company with tickers: KLRS
CIK
1754068
CUSIP
482929106
Shares Outstanding
23,792,278
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $10,354,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Research & Development | $6,030,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Operating Income | $-10,354,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Net Income | $-10,196,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| EPS (Basic) | $-2.52 | USD/shares | 2025-03-31 | 10-Q | 2026-05-12 |
| EPS (Diluted) | $-2.52 | USD/shares | 2025-03-31 | 10-Q | 2026-05-12 |